Acute Heart Failure Clinical Trial
Official title:
Investigating All-Cause 30-Day Hospital Readmisisons in Patients Discharged From a Tertiary Teaching Hospital With Acute Decompensated Heart Failure Diagnosis
This is a dissertation study which is divided into three different studies in order to answer
the main research question (Study 3). The primary aim of this research (dissertation) is to
investigate all-cause 30-day hospital readmission using functional mobility (5mWT, 30STS,
6MWT, TUG), psychosocial attributes (KCCQ-12, HADS, ESSI), adherence to home exercise
program, participation in a supervised exercise program, and number of follow up checkups
with physicians or advanced health providers of patients with Acute Decompensated Heart
Failure (ADHF) diagnosis who were discharged from a tertiary teaching hospital.
Study 1: What is the effect of acute physical therapy on functional ability in individuals
admitted with ADHF? Study 2: What is the effect of acute physical therapy on psychosocial
attributes in individuals admitted with ADHF? Study 3: Which factors such as functional
mobility (5mWT, 30STS, 6MWT, TUG), psychosocial attributes (KCCQ-12, HADS, ESSI), adherence
to home exercise program, participation in a supervised exercise program, and number of
follow up checkups with physicians or advanced health providers predict all-cause 30-day
hospital readmission in patients discharged from a tertiary, teaching hospital with ADHF
diagnosis?
The research plan is to investigate how acute physical therapy can play a big role in
lowering 30-day hospital readmission in patients discharged with acute decompensated heart
failure (ADHF). Several factors will be used to investigate and predict 30-day hospital
readmission. Such factors are (1) functional mobility; 2) psychosocial attributes; (3) number
of follow ups with providers; (4) adherence to home exercise program; (5) and participation
in a supervised exercise program. Functional mobility will be measured by four different
functional outcome measurements such as 5 meter walk test (5mWT), 30 seconds sit to stand
test (30STS), six minute walk test (6MWT), and time up and go test (TUG). The psychosocial
attributes will be measured by three different, pen and paper, self-survey questionnaires
namely Kansas City Cardiomyopathy Questionnaire-12 (KCCQ12), Hospital Anxiety and Depression
Scale (HADS), ENRICHD Social Support Instrument (ESSI). Moreover, once the patient returns
home, two phone surveys will be conducted (every two weeks) for a period of 30 days of
hospital discharge as a follow up.
For the outcome measurements, the 5mWT is a simple test to measure individual's gait
(walking) speed. The 30STS is a simple and easy test to complete in assessing functional
lower extremity strength. The 30STS asks individual to stand up (assuming erect posture as
much as possible with or without hands support) as many as possible from a regular chair with
arm rest within 30 seconds timeframe. The 6MWT is simple and practical test is to measure
aerobic capacity by measuring distance of an individual's ability to walk for 6 minutes. The
TUG is to measure the time in seconds for a person to rise from sitting from a standard arm
chair, rise, walk 10 feet, walk back to the previous arm chair, and sit down. The objective
of the TUG test is to classify patient's fall risk. In addition, the functional mobility,
basing on the functional outcome measures conducted, will be further assessed at the end of
physical therapy service at the hospital by using Global Rating of Scale (GROC). The GROC is
a self-survey using 5 point Likert scale, measuring how patient perceives the overall degree
of change of improvement or perhaps a lack of improvement.
For the Psychosocial Measures, the Kansas City Cardiomyopathy Questionnaire (KCCQ)-12 is a
shorter version of the original KCCQ tool. The objective of this test is to quantify
self-measurement of physical function, symptoms, social function, self-efficacy and
knowledge, and quality of life as it relates to their own heart failure diagnosis. The
Hospital Anxiety and Depression Scale (HADS) is a self-reported questionnaire designed to
measure the levels of anxiety and depression that an individual is experiencing. The
objective of this tool is to serve as a screening tool to identify individuals who may suffer
from anxiety and depression. The ENRICHD Social Support Instrument (ESSI) is a seven-item
self-report survey that assesses patient's belief of their social support attributes
(emotional, instrumental, informational, and appraisal).
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT02151383 -
Pharmacokinetics & Safety of Serelaxin on Top of Standard of Care Therapy in Pediatric Patients With Acute Heart Failure
|
Phase 2 | |
Completed |
NCT02135835 -
A Study to Evaluate the Efficacy and Safety of Shenfu Zhusheye in Patients With Acute Heart Failure
|
Phase 4 | |
Recruiting |
NCT05556044 -
Empagliflozin for New On-set Heart Failure Study Regardless of Ejection Fraction
|
Phase 3 | |
Recruiting |
NCT04363697 -
Dapagliflozin and Effect on Cardiovascular Events in Acute Heart Failure -Thrombolysis in Myocardial Infarction 68 (DAPA ACT HF-TIMI 68)
|
Phase 4 | |
Completed |
NCT02122640 -
Evaluation of Acute Cardiogenic Dyspnoea With Thorax Echography and Pro-BNP in the Emergency Department
|
N/A | |
Completed |
NCT01193998 -
Impact of Validated Diagnostic Prediction Model of Acute Heart Failure in the Emergency Department
|
N/A | |
Not yet recruiting |
NCT01211886 -
Utility of Brain Natriuretic Peptide (BNP) in Patients With Type IV Cardio-renal Syndrome Admitted to the Intensive Care Unit (ICU)
|
N/A | |
Not yet recruiting |
NCT06465498 -
Investigating aCute heArt failuRe Decongestion Guided by Lung UltraSonography
|
N/A | |
Recruiting |
NCT05276219 -
Optimized Treatment of Pulmonary Edema or Congestion
|
Phase 4 | |
Recruiting |
NCT05392764 -
Early Treatment With a Sodium-glucose Co-transporter 2 Inhibitor in High-risk Patients With Acute Heart Failure
|
Phase 3 | |
Recruiting |
NCT03157219 -
Manipal Heart Failure Registry (MHFR)
|
N/A | |
Completed |
NCT06024889 -
Acute Effects of Furosemide on Hemodynamics and Pulmonary Congestion in Acute Decompensated Heart Failure.
|
Phase 1/Phase 2 | |
Terminated |
NCT04174794 -
Investigating Reduction of aCute heArt Failure Readmission With Lung UltraSound-preliminary Trial
|
||
Recruiting |
NCT05972746 -
Telemonitoring Program in the Vulnerable Phase After Hospitalization for Heart Failure
|
N/A | |
Enrolling by invitation |
NCT02258984 -
Can the Venus 1000 Help Clinicians Treat Patients With Severe Sepsis or Acute Heart Failure? The CVP Trial
|
N/A | |
Completed |
NCT02141607 -
Evolution of Molecular Biomarkers in Acute Heart Failure Induced by Shock
|
||
Completed |
NCT01870778 -
Efficacy, Safety and Tolerability of Serelaxin When Added to Standard Therapy in AHF
|
Phase 3 | |
Recruiting |
NCT05986773 -
Diuretic Strategies in Acute Heart Failure Patients at High Risk for Diuretic Resistance
|
Phase 4 | |
Recruiting |
NCT04163588 -
Sequential Nephron Blockade in Acute Heart Failure
|
Phase 3 | |
Recruiting |
NCT03717636 -
Early or Non-revoked in Hospital-day in Patients With Acute Heart Failure
|
N/A |